Journal of Atherosclerosis and Thrombosis This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Prognostic Implications of the Acute Lipid Levels in Stroke Patients
J Atheroscler Thromb. 2024 Apr 23. doi: 10.5551/jat.ED261. Online ahead of print.NO ABSTRACTPMID:38658326 | DOI:10.5551/jat.ED261 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 24, 2024 Category: Cardiology Authors: Takao Hoshino Source Type: research

Which Metabolites are Involved in the Pathogenesis of Atherosclerotic Disease in NAFLD?
J Atheroscler Thromb. 2024 Apr 19. doi: 10.5551/jat.ED260. Online ahead of print.NO ABSTRACTPMID:38644202 | DOI:10.5551/jat.ED260 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 21, 2024 Category: Cardiology Authors: Kozo Tanno Source Type: research

Atrial Cardiomyopathy Predicts the Functional Outcome and Mortality in Stroke Patients
CONCLUSIONS: ACM may serve as a novel predictor of a poor long-term functional outcome in patients with NCS. Elevated NT-pro BNP levels (＞250 pg/ml) were found to be associated with a higher risk of all-cause mortality. These findings warrant further validation in multicenter studies.PMID:38644203 | DOI:10.5551/jat.64756 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 21, 2024 Category: Cardiology Authors: Xinjing Liu Yuying Wang Lan Ding Ruiyao Hu Yige Zhang Wan Zhang Lulu Pei Yuan Cao Hui Fang Kai Liu Shilei Sun Jun Wu Ferdinando S Buonanno Mingming Ning Yuming Xu Bo Song Source Type: research

Impact of Age on Prescribing Patterns of Cardiovascular Medications in Older Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease: A Cross-Sectional Study
CONCLUSIONS: This study suggests that age is a potential barrier to the treatment of patients with CKD and highlights the need to establish individualized treatment strategies for cardiovascular protection in this population.PMID:38631869 | DOI:10.5551/jat.64798 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 17, 2024 Category: Cardiology Authors: Shigeru Tanaka Hiromasa Kitamura Kazuhiko Tsuruya Takanari Kitazono Toshiaki Nakano FKR Study Collaboration Group Source Type: research

In the Beginning, Lipoproteins Cross the Endothelial Barrier
J Atheroscler Thromb. 2024 Apr 13. doi: 10.5551/jat.RV22017. Online ahead of print.ABSTRACTAtherosclerosis begins with the infiltration of cholesterol-containing lipoproteins into the arterial wall. White blood cell (WBC)-associated inflammation follows. Despite decades of research using genetic and pharmacologic methods to alter WBC function, in humans, the most effective method to prevent the initiation and progression of disease remains low-density lipoprotein (LDL) reduction. However, additional approaches to reducing cardiovascular disease would be useful as residual risk of events continues even with currently effect...
Source: Journal of Atherosclerosis and Thrombosis - April 14, 2024 Category: Cardiology Authors: Ira J Goldberg Ainara G Cabodevilla Waqas Younis Source Type: research

Joint Association of Lipoprotein(a) and a Family History of Coronary Artery Disease with the Cardiovascular Outcomes in Patients with Chronic Coronary Syndrome
CONCLUSIONS: The present study is the first to suggest that Lp(a) could be used to predict MACEs in CCS patients with or without FHx; however, its prognostic significance was more noteworthy in patients with FHx.PMID:38616111 | DOI:10.5551/jat.64693 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 14, 2024 Category: Cardiology Authors: Hui-Hui Liu Sha Li Yan Zhang Yuan-Lin Guo Cheng-Gang Zhu Na-Qiong Wu Ying Gao Rui-Xia Xu Qian Dong Jian-Jun Li Source Type: research

Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial
CONCLUSIONS: XR (0.2 and 0.4 mg/day) was non-inferior to IR (0.2 mg/day). XR 0.4 mg/day demonstrated a more potent triglyceride-lowering effect than XR 0.2 mg/day and should be considered for patients with high triglyceride levels.PMID:38616112 | DOI:10.5551/jat.64677 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 14, 2024 Category: Cardiology Authors: Hidenori Arai Shizuya Yamashita Eiichi Araki Koutaro Yokote Ryohei Tanigawa Ayumi Saito Sayumi Yamasaki Hideki Suganami Shun Ishibashi Source Type: research

LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Ameliorates Endothelial Dysfunction in Diabetic C57BL/6 Mice
CONCLUSION: LCZ696 ameliorated diabetes-induced endothelial dysfunction by increasing the bioavailability of ANP. Our findings suggest that LCZ696 has a vascular protective effect in a diabetic model and highlight that it may be more effective than valsartan.PMID:38616113 | DOI:10.5551/jat.64468 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 14, 2024 Category: Cardiology Authors: Uugantsetseg Munkhjargal Daiju Fukuda Juri Maeda Tomoya Hara Shintaro Okamoto Oyunbileg Bavuu Takayuki Yamamoto Masataka Sata Source Type: research